![Propesor Adam Frampton , [object Object]](/_next/image?url=https%3A%2F%2Fd3fzwscyjtgllx.cloudfront.net%2Fuploads%2Fimages%2F2101217150711213236814.jpg&w=3840&q=60)
General at Hepato-Pancreato-Biliary Surgeon
Kumonsulta sa:
Professor Adam Frampton is a Consultant General and Hepato-Pancreato-Biliary Surgeon in Surrey and London. He is skilled in treating complex gallstone disease (cholecystectomy), and performing groin and abdominal wall hernia repair, and specialises in liver, pancreatic, and biliary surgery. He has a specialist interest in investigating and treating all benign and cancerous disorders of the liver, pancreas, and biliary-tract.
After qualifying from Imperial College London in 2003, he went on to gain an MSc in General Surgical Practice from the University of Kent in 2011, before returning to Imperial College London, where he was awarded a PhD in 2014 for his work on complex gene interactions in pancreatic cancer.
He underwent basic and higher surgical training in London and Surrey, and became a fellow of the Royal College of Surgeons of England in 2018. During his training he undertook several international observerships in both the USA and Europe, and has gained exceptional experience in his field.
Professor Frampton is extremely passionate about research, and aims to translate new discoveries directly into improved patient care. He is one of the most knowledgeable specialists in his field and has won numerous awards for his research including the Moynihan prize, the Sir James Fraser Travelling Fellowship and the Hunterian Professorship. He is currently tenured Assoc. Professor in Surgical Oncology and Head of Oncology at the University of Surrey where he leads a laboratory group and supervises BSc, MSc, MD and PhD students.
His current research includes investigating the molecular aspects of pancreatic, liver and biliary-tract cancers, including the development of clinically useful biomarkers and targeted anti-cancer treatments, and understanding the tumour microenvironment and mechanisms of metastasis (cancer spread), topics on which he regularly publishes his findings in peer-reviewed journals.
Professor Frampton’s research is at the “cutting-edge” and consequently he offers a highly analytical and evidence-based approach for his patients.
